Abstract
Background Hepatitis E virus (HEV) is endemic in many resource-poor countries. Despite an available vaccine, data on HEV-associated mortality are scarce, hindering informed decisions. This study aims to estimate the population-based rate of HEV-specific mortality in Bangladesh.
Methods During December 2014-September 2017, we conducted surveillance in six tertiary hospitals in Bangladesh. Patients aged ≥14 years with acute jaundice were recruited, tested for IgM anti-HEV, and followed up post-discharge. A mortality survey in the hospital catchment areas identified deaths associated with acute jaundice, including maternal, stillbirths and neonatal deaths delivered by a mother with acute jaundice during pregnancy, confirmed by two independent physicians reviewing verbal autopsy data.
Findings Out of 1,925 patients with acute jaundice identified and enrolled in the surveillance hospitals, 302 died, with 28 (9%) testing positive for IgM anti-HEV. In the hospital catchment areas, the team identified 587 jaundice-associated deaths, including 25 maternal deaths. Combining hospital-based surveillance and mortality survey data, the study estimated 986 (95% CI: 599-1338) HEV-associated deaths annually among individuals aged ≥14 years in Bangladesh, including 163 (95% CI: 57-395) maternal deaths. Additionally, 279 (95% CI: 101-664) stillbirths and 780 (95% CI: 365-1,297) neonatal deaths were attributed to HEV infection annually.
Interpretation Prior Global Burden of Disease studies presented wildly varying modeling estimates of HEV-associated annual deaths, ranging from 50,000 in 2013 to 1,932 in 2019. This study is the first to directly measure population-based estimates of mortality in Bangladesh, which can be used to determine the cost-effectiveness of hepatitis E vaccination and other interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Centers for Disease Control and Prevention (CDC), United States
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the institutional review board of the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) (Protocol # PR-14060).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: The Centers for Disease Control and Prevention (CDC), United States
Data Availability
All data produced in the present study are available upon reasonable request to the authors
